SCHEMBL580229

SCHEMBL580229

O=C(O)c1cc(NCc2c(F)c(F)c(C(F)(F)F)c(F)c2F)ccc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.55
STING1 Q86WV6 1/20 0.55
EGFR P00533 7/20 0.53
NOX4 Q9NPH5 3/20 0.53
ALDH1A1 P00352 3/20 0.53
MAPT P10636 2/20 0.53
RGS12 O14924 1/20 0.53
LCK P06239 1/20 0.53
CAMKK2 Q96RR4 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
KDM4C Q9H3R0 5/20 0.52
LDHA P00338 1/20 0.39
LDHB P07195 1/20 0.39
PTGS2 P35354 1/20 0.39
HAO1 Q9UJM8 1/20 0.39
KDM4E B2RXH2 2/20 0.39
PTPN1 P18031 1/20 0.38
SYK P43405 1/20 0.38
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium SCHEMBL29515374 0.99 PPARA (0.54) PPARASTING1EGFRNOX4ALDH1A1
SCHEMBL3996747 0.99 PPARA (0.54) PPARASTING1EGFRNOX4ALDH1A1
SCHEMBL3996778 0.99 PPARA (0.54) PPARASTING1EGFRNOX4ALDH1A1
SCHEMBL3996092 0.99 PPARA (0.54) PPARASTING1EGFRNOX4ALDH1A1
Sulfuric Acid SCHEMBL28638816 0.95 PPARA (0.51) PPARASTING1EGFRNOX4ALDH1A1
SCHEMBL499950 0.89 PPARA (0.63) PPARASTING1EGFRNOX4ALDH1A1
SCHEMBL30473063 0.89 PPARA (0.63) PPARASTING1EGFRNOX4ALDH1A1
SCHEMBL3955043 0.89 PPARA (0.43) PPARASTING1EGFRNOX4ALDH1A1
Lithium Ion SCHEMBL3996773 0.88 PPARA (0.42) PPARASTING1EGFRNOX4ALDH1A1
SCHEMBL3996087 0.88 PPARA (0.42) PPARASTING1EGFRNOX4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12576091-B2 Preparation method of salfaprodil freeze-dried powder injection, and product and use thereof GNT PHARMA CO., LTD. (KR) 2026-03-17 US claimed
US-20260027076-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY GNT PHARMA CO LTD (KR) 2026-01-29 US claimed
US-12433861-B2 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy GNT PHARMA CO., LTD. (KR) 2025-10-07 US claimed
US-20230390231-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY GNT PHARMA CO., LTD. (KR) 2023-12-07 US claimed
US-11826329-B2 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy GNT PHARMA CO., LTD. (KR) 2023-11-28 US claimed
US-20230270757-A1 PREPARATION METHOD OF SALFAPRODIL FREEZE-DRIED POWDER INJECTION, AND PRODUCT AND USE THEREOF GNT PHARMA CO., LTD. (KR) 2023-08-31 US claimed
EP-4190314-A1 PREPARATION METHOD OF SALFAPRODIL FREEZE-DRIED POWDER INJECTION, AND PRODUCT AND USE THEREOF GNT Pharma Co., Ltd (KR) 2023-06-07 EP claimed
EP-4117648-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY GNT Pharma Co., Ltd (KR) 2023-01-18 EP claimed
CN-115515573-A Compositions and methods for treating reperfusion injury or bleeding following recanalization GNT制药有限公司 2022-12-23 CN claimed
CN-108164431-B 2-hydroxy-5- (2,3,5, 6-tetrafluoro-4-trifluoromethyl benzylamino) benzoic acid and preparation method thereof 浙江普洛家园药业有限公司 2021-10-08 CN claimed
US-20070049565-A1 Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2007-03-01 US claimed
WO-2006126846-A1 PROCESS OF PREPARATION OF SUBSTITUTED TETRAFLUOROBENZYLANILINE COMPOUND AND ITS PHARMACEUTICALLY APPROVED SALTS CHOONGWAE PHARMA CORPORATION (KR) 2006-11-30 WO claimed
WO-2006126825-A1 COMPOSITION COMPRISING TETRAFLUOROBENZYL DERIVATIVES OR SALTS OF THEREOF FOR INJECTION CHOONGWAE PHARMA CORPORATION (KR) 2006-11-30 WO claimed
US-20060235239-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH CO., LTD. (KR) 2006-10-19 US claimed
CN-1738627-A Method for inhibiting necrosis induced by neurotrophic factor NEUROTECH PHARMACEUTICALS CO L (KR) 2006-02-22 CN claimed
CN-1668576-A Tetrafluorobenzyl derivatives and pharmaceutical composition for treating and preventing acute and chronic neurodegenerative diseases of central nervous system containing the same NEUROTECH CO LTD (KR) 2005-09-14 CN claimed
US-6927303-B2 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH CO., LTD. (KR) 2005-08-09 US claimed
EP-1551793-A1 TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME Neurotech Co., Ltd. (KR) 2005-07-13 EP claimed
US-20040209957-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2004-10-21 US claimed
WO-2004000786-A1 TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME NEUROTECH CO., LTD. (KR) 2003-12-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12433861-B2 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy PLAT, SERPINE1, SERPINC1 PPARA 3027/4885STING1 2135/4885EGFR 100/4885
US-11826329-B2 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy PLAT, SERPINE1, SERPINC1 PPARA 3027/4885STING1 2135/4885EGFR 100/4885
US-20230390231-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY PLAT, SERPINE1, SERPINC1 PPARA 3027/4885STING1 2135/4885EGFR 100/4885
US-20260027076-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY FGB, PLAT, CTSH PPARA 348/4885STING1 3196/4885EGFR 169/4885
US-20230270757-A1 PREPARATION METHOD OF SALFAPRODIL FREEZE-DRIED POWDER INJECTION, AND PRODUCT AND USE THEREOF PGF, SALL4, FIBP PPARA 146/4885STING1 3632/4885EGFR 3902/4885
US-12576091-B2 Preparation method of salfaprodil freeze-dried powder injection, and product and use thereof PGF, PGA5, PDE5A PPARA 704/4885STING1 3602/4885EGFR 4233/4885
US-20070049565-A1 Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction BAD, MAP1LC3B, XIAP PPARA 4072/4885STING1 3607/4885EGFR 2579/4885
US-20060235239-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same HTT, BDNF, APP PPARA 289/4885STING1 4579/4885EGFR 510/4885
US-20040209957-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same HTT, BDNF, APP PPARA 289/4885STING1 4579/4885EGFR 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.